octanate 250 i.u.
octapharma pharmazeutika produktionsges.m.b.h., rakúsko - koagulačný faktor viii - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
octanate 500 i.u.
octapharma pharmazeutika produktionsges.m.b.h., rakúsko - koagulačný faktor viii - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
octanate 1000 i.u.
octapharma pharmazeutika produktionsges.m.b.h., rakúsko - koagulačný faktor viii - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
octagam 5 %
octapharma (ip) sprl, belgicko - normálne ľudské imunoglobulíny na intravenózne použitie - 59 - immunopraeparata
gammanorm 165 mg/ ml
octapharma (ip) sprl, belgicko - normálne ľudské imunoglobulíny na extravenózne použitie - 59 - immunopraeparata
fibryga
octapharma (ip) sprl, belgicko - Ľudský fibrinogén - 75 - substitutio sanguinis (a krvnÉ derivÁty)
panzyga
octapharma (ip) sprl, belgicko - normálne ľudské imunoglobulíny na intravenózne použitie - 59 - immunopraeparata
octagam 10 %
octapharma (ip) sprl, belgicko - normálne ľudské imunoglobulíny na intravenózne použitie - 59 - immunopraeparata
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
dimethyl fumarate teva
teva gmbh - dimetylfumarát - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresíva - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).